Despite the fact that the medications used to treat abnormal bone conditions often induce @entity2530 of the jaw (ONJ), previous attempts to establish an animal model for ONJ have shown insufficient consideration for this important prerequisite for the development of the disease. The purpose of this study was to establish an animal model with the most common @entity2331 , @entity170 . Ninty-six @entity35 were randomly divided into ovariectomy (Ov) group (n=48) and sham-operated group (n=48). Six weeks after Ov or sham surgery, @entity35 in each group were subdivided into @entity5520 group (n=36 each) and control group (n=12 each) and injected with @entity4381 and normal saline, respectively, once a week. After additional 6weeks, surgical intervention was performed, and the injections were continued for 8 more weeks. The animals were then sacrificed for further macroscopic, histological, histomorphometric, radiological, and bone biomarker investigations. As histologically determined, the Ov group (77.8%) showed higher ONJ prevalence compared to the sham group (47.2%; P<0.05). Micro-structural and histomorphometric assessments revealed that @entity35 with ONJ (ONJ group) presented with deteriorated bone architectures with higher necrotic bone fraction and lower number of osteoclasts (P<0.05). Compared to the sham-operated ONJ group, the Ov ONJ group showed significantly lower values of Tb.N, Tb.Sp, Conn.D, N.Oc/T.Ar, and TRACP 5b and CTX/TRACP (P<0.05). The ovariectomized @entity35 model in this study successfully mimicked @entity1 @entity75 with an underlying @entity79 and showed different bone characteristics than that of the previous ONJ model. Based on the differences, further researches for investigating pathophysiology of ONJ, including various pharmacological responses for deteriorated bone environment, are required.

Animal model for medication-related @entity2530 of the jaw with precedent XXXX .

@entity1 :: ('9606', 'Species') :: ['human'] @entity75 :: ('MESH:D001927', 'Disease') :: ['ONJ lesions'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity5520 :: ('D004164', 'Chemical') :: ['bisphosphonate'] @entity2331 :: ('MESH:D001851', 'Disease') :: ['metabolic bone disease'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronic acid'] @entity2530 :: ('MESH:D010020', 'Disease') :: ['osteonecrosis']
@entity2331 :: (MESH:D001851,Disease) :: ['metabolic bone disease']
